Navigation Links
Continued Recognition for Excellence; Accelovance Named 2011 "Best CRO"
Date:4/18/2011

ROCKVILLE, Md., April 18, 2011 /PRNewswire-USNewswire/ -- Accelovance, a privately held clinical research company has been named the "Best Contract Research Organization (CRO)" for a third consecutive year. The World Vaccine Congress, held last week at the Gaylord National Hotel and Convention Center, Washington, D.C., hosted its annual Vaccine Industry Excellence (ViE) Awards to honor and generate recognition of the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry over the past 12 months.

"Recognition from our colleagues and clients at this level is truly an honor. I believe consistency in performance, value and partnership is what defines our company's success," said Stephen J. Trevisan, President and CEO.

The "Best CRO" category is designed to highlight the importance of contract research services within the vaccine industry; Accelovance has won the award three of the four years it has been a finalist. An international panel of judges evaluates category finalists on quality of work, range of services, strength of client relationships and performance.

"Quality and commitment are what define our organization," remarked Lee Barsky, Vice President of CRO Services. "It is equally rewarding to see how our diverse service offering helps Sponsors maintain growth despite challenging times in the industry."

Accelovance supports the business needs of biotech and small/mid pharma companies with cost-effective, flexible solutions that extend beyond traditional CRO services. Recently, the balanced perspective of study management and site operations positioned Accelovance to successfully rescue two Phase III therapeutic vaccine programs. Additionally, several Phase I vaccine studies in support of novel manufacturing or delivery methods are currently underway.

Headquartered in Rockville, Maryland, Accelovance has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies. Accelovance offers wholly-owned, research-dedicated clinical sites to Sponsors and CROs that bring greater control, predictability, and quality assurance to vaccine programs. Additionally, the Company tailors its offering of full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets a Sponsor's needs. Accelovance has a 100% owned subsidiary providing CRO services in China. These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.

For more information, visit the company's website at http://www.accelovance.com.

Media Contact:
Angie Wing
Phone: 240.238.4921
awing@accelovance.com


'/>"/>
SOURCE Accelovance
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
2. DSM Biomedical Announces Continued Partnership with Spinelab
3. HSC Trial Shows Continued Significant Hair Growth at One Year Follow-up
4. Continued Demand Makes Monsanto and Agriculture Unique Investment Opportunities, Global Seeds and Traits Lead to Tell Investors
5. China Sky One Medical Confirms Continued Sale of Seven of Eight Products on the Ministry of Healths Warning List
6. GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress
7. Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market
8. Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan
9. New Generation Biofuels Receives NASDAQ Notice of Noncompliance with Continued Listing Requirements
10. Avid Bioservices Expands Executive Team as it Prepares for Continued Growth
11. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case ... Denmark detail how a patient who developed lymphedema after being treated for breast cancer ... could change the paradigm for dealing with this debilitating, frequent side effect of cancer ...
Breaking Biology Technology:
(Date:6/22/2016)... WASHINGTON , June 22, 2016 On ... highly-anticipated call to industry to share solutions for the ... by U.S. Customs and Border Protection (CBP), explains that ... nationals are departing the United States ... criminals, and to defeat imposters. Logo - ...
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
Breaking Biology News(10 mins):